The Effect of Vortioxetine on Health-related Quality of Life in Patients with Major Depressive Disorder

Clinical Therapeutics

Volumn 37, Issue 10, 2015, Pages 2309-2323.e6

  Florea, Ioana ^a   Danchenko, Natalya ^b   Brignone, Melanie ^b   Loft, Henrik ^a   Rive, Benoit ^b   Abetz Webb, Linda ^c  

^a H LUNDBECK A S   (Denmark)

^b Lundbeck   (France)

^c Patient Centered Outcomes Assessments Ltd   (United Kingdom)

Author keywords

antidepressant; health related quality of life; major depressive disorder; patient reported outcomes; vortioxetine

Indexed keywords

PLACEBO; VORTIOXETINE; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ARTICLE; ASSESSMENT OF HUMANS; EFFECT SIZE; EMOTION; EUROQOL 5 DIMENSION QUESTIONNAIRE; HEALTH STATUS QUESTIONNAIRE 12; HUMAN; MAJOR DEPRESSION; MENTAL HEALTH; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SOCIAL INTERACTION; TREATMENT DURATION; ADULT; AGED; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH STATUS; MALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH STATUS; HUMANS; MALE; PIPERAZINES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SULFIDES; SURVEYS AND QUESTIONNAIRES;

EID: 84945461623     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.08.008     Document Type: Article

References (97)

1. J. Angst How recurrent and predictable is depressive disorder? S. Montgomery, F. Rouillon, Long-Term Treatment of Depression; Perspectives in Psychiatry. Volume 3 1992 John Wiley & Sons Chichester, UK 13
2. S.A. Montgomery Why do we need new and better antidepressants? Int Clin Psychopharmacol 21 Suppl 1 2006 S1 S10
3. M.E. Thase Preventing relapse and recurrence of depression: a brief review of therapeutic options CNS Spectr 11 2006 12 21
4. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br J Psychiatry 178 2001 234 241
5. American Psychiatric Association (APA). Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. Third ed. Arlington, VA: American Psychiatric Association; 2010
6. E.S. Paykel, T. Brugha, and T. Fryers Size and burden of depressive disorders in Europe Eur Neuropsychopharmacol 15 2005 411 423
7. A. Khan, S.R. Khan, R.M. Leventhal, and W.A. Brown Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database Int J Neuropsychopharmacol 4 2001 113 118
8. R.C. Kessler, P. Berglund, O. Demler, and et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA 289 2003 3095 3105
9. K.B. Wells, A. Stewart, R.D. Hays, and et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study JAMA 262 1989 914 919
10. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, and et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR∗D report J Clin Psychiatry 67 2006 185 195
11. M.H. Trivedi Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission J Clin Psychiatry 70 Suppl 6 2009 26 31
12. P.S. Wang, G. Simon, and R.C. Kessler The economic burden of depression and the cost-effectiveness of treatment Int J Methods Psychiatr Res 12 2003 22 33
13. J.A. Israel The impact of residual symptoms in major depression Pharmaceuticals 3 2010 2426 2440
14. G.I. Papakostas, T. Petersen, Y. Mahal, and et al. Quality of life assessments in major depressive disorder: a review of the literature Gen Hosp Psychiatry 26 2004 13 17
15. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, and et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice Am J Psychiatry 163 2006 28 40
16. D. Warden, A.J. Rush, M.H. Trivedi, and et al. The STAR∗D Project results: a comprehensive review of findings Curr Psychiatry Rep 9 2007 449 459
17. M.C. ten Doesschate, M.W. Koeter, C.L. Bockting, and A.H. Schene Health related quality of life in recurrent depression: a comparison with a general population sample J Affect Disord 120 2010 126 132
18. E.J. Daly, M.H. Trivedi, S.R. Wisniewski, and et al. Health-related quality of life in depression: a STAR∗D report Ann Clin Psychiatry 22 2010 43 55
19. European Medicines Agency: CHMP reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP); 2005.
20. A. Pitkanen, M. Valimaki, J. Endicott, and et al. Assessing quality of life in patients with schizophrenia in an acute psychiatric setting: reliability, validity and feasibility of the EQ-5D and the Q-LES-Q Nord J Psychiatry 66 2012 19 25
21. S.D. Keller, M.S. Bayliss, J.E. Ware Jr., and et al. Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods Health Serv Res 32 1997 367 384
22. N. Danchenko, B. Rive, S. Pendlebury, and L. Abetz-Webb Assessing health-related quality of life (HRQoL) in major depressive disorder (MDD): do commonly used instruments meet EMA requirements for psychometric properties and content relevance? [abstract] Value Health 16 2013 A64
23. C. Sanchez, K.E. Asin, and F. Artigas Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data Pharmacol Ther 145C 2015 43 57
24. R. Jain, A.R. Mahableshwarkar, P. Jacobsen, and et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder Int J Neuropsychopharmacol 16 2013 313 321
25. N. Henigsberg, A.R. Mahableshwarkar, P. Jacobsen, and et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder J Clin Psychiatry 73 2012 953 959
26. D.S. Baldwin, H. Loft, and M. Dragheim A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD) Eur Neuropsychopharmacol 22 2012 482 491
27. E. Alvarez, V. Perez, M. Dragheim, and et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder Int J Neuropsychopharmacol 15 2012 589 600
28. J.P. Boulenger, H. Loft, and C.K. Olsen Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder Int Clin Psychopharmacol 29 2014 138 149
29. C. Katona, T. Hansen, and C.K. Olsen A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder Int Clin Psychopharmacol 27 2012 215 223
30. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
31. M. Maruish User's Manual for the SF-36v2® Health Survey 2011 QualityMetric, Inc Lincoln, RI
32. J. Endicott, J. Nee, W. Harrison, and R. Blumenthal Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure Psychopharmacol Bull 29 1993 321 326
33. J. Endicott, K. Rajagopalan, M. Minkwitz, W. Macfadden BOLDER Study Group A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life Int Clin Psychopharmacol 22 2007 29 37
34. EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
35. D. Radosevich, and M. Pruitt Twelve-item Health Status Questionnaire (HSQ-12) Version 2.0 user's guide 1996 Health Outcomes Institute Bloomington, MN
36. PROQOLID Database. [ http://www.proqolid.org/ ]. Accessed 16 October, 2013
37. Optum. SF-36 Health Survey Update [ sf-36.org/tools/sf36.shtml#MODEL ]. Accessed 16 October, 2013
38. Clinical Trials Clinicaltrials.gov 2013 Accessed 16 October, 2013
39. C.I. Hung, C.Y. Liu, C.H. Yang, and S.J. Wang Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder Psychiatry Clin Neurosci 66 2012 8 16
40. D.G. Perahia, D. Quail, D. Desaiah, and et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques J Clin Psychiatry 69 2008 95 105
41. T.N. Wise, C.G. Wiltse, D.V. Iosifescu, and et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity Int J Clin Pract 61 2007 1283 1293
42. M.H. Trivedi, D.L. Dunner, S.G. Kornstein, and et al. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release J Affect Disord 126 2010 420 429
43. Y.F. Zou, Y. Wang, P. Liu, and et al. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine Hum Psychopharmacol 25 2010 145 152
44. P. Chokka, and M. Legault Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial Depress Anxiety 25 2008 E173 E181
45. S. Mohamed, K. Osatuke, M. Aslam, and J. Kasckow Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial Am J Geriatr Pharmacother 4 2006 201 209
46. J.M. Hartman, A. Berger, K. Baker, and et al. Quality of life and pain in premenopausal women with major depressive disorder: the POWER Study Health Qual Life Outcomes 4 2006 2
47. J. Irvine, J. Firestone, L. Ong, and et al. A randomized controlled trial of cognitive behavior therapy tailored to psychological adaptation to an implantable cardioverter defibrillator Psychosom Med 73 2011 226 233
48. J.B. Diniz, R.G. Shavitt, V. Fossaluza, and et al. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder J Clin Psychopharmacol 31 2011 763 768
49. C. Belotto-Silva, J.B. Diniz, D.M. Malavazzi, and et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial J Anxiety Disord 26 2012 25 31
50. C.M. Canuso, A. Grinspan, A. Kalali, and et al. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone Int Clin Psychopharmacol 25 2010 155 164
51. D.J. Muzina, K. Gao, D.E. Kemp, and et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial J Clin Psychiatry 72 2011 813 819
52. Ware J, Jr., Kosinski M, Dewey JE: How to score verion 2 of the SF-36. In SF-36 Health Survery: manual and interpretation guide. Volume 3rd. Lincoln, RI: QualityMetric Incorporated; 2001
53. J. Endicott, J.M. Russell, J. Raskin, and et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies J Clin Psychiatry 68 2007 518 524
54. P.A. Newhouse, K.R. Krishnan, P.M. Doraiswamy, and et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients J Clin Psychiatry 61 2000 559 568
55. B. Bortnick, N. El-Khalili, M. Banov, and et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study J Affect Disord 128 2011 83 94
56. M.H. Rapaport, R.B. Lydiard, C.D. Pitts, and et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial J Clin Psychiatry 70 2009 46 57
57. L.S. Schneider, J.C. Nelson, C.M. Clary, and et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression Am J Psychiatry 160 2003 1277 1285
58. A. Sir, R.F. D'Souza, S. Uguz, and et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms J Clin Psychiatry 66 2005 1312 1320
59. M.H. Trivedi, T.A. Pigotti, P. Perera, and et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder J Clin Psychiatry 65 2004 1356 1364
60. R. Rabin, and F. de Charro EQ-5D: a measure of health status from the EuroQol Group Ann Med 33 2001 337 343
61. C.F. Reynolds 3rd, M.A. Dew, B.G. Pollock, and et al. Maintenance treatment of major depression in old age N Engl J Med 354 2006 1130 1138
62. P. Barone, W. Poewe, S. Albrecht, and et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial Lancet Neurol 9 2010 573 580
63. H.H. Konig, A. Born, O. Gunther, and et al. Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders Health Qual Life Outcomes 8 2010 47
64. O.H. Gunther, C. Roick, M.C. Angermeyer, and H.H. Konig The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning J Affect Disord 105 2008 81 91
65. J.R. Calabrese, R.M. Hirschfeld, M. Reed, and et al. Impact of bipolar disorder on a U.S. community sample J Clin Psychiatry 64 2003 425 432
66. T. Pettit, G. Livingston, M. Manela, and et al. Validation and normative data of health status measures in older people: the Islington study Int J Geriatr Psychiatry 16 2001 1061 1070
67. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
68. O. Siddiqui, H.M. Hung, and R. O'Neill MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets J Biopharm Stat 19 2009 227 246
69. S. Leucht, S. Hierl, W. Kissling, and et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses Br J Psychiatry 200 2012 97 106
70. Murray CJL, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: The Harvard School of Public Health; 1996.
71. T.B. Ustun, J.L. Ayuso-Mateos, S. Chatterji, and et al. Global burden of depressive disorders in the year 2000 Br J Psychiatry 184 2004 386 392
72. C.C. Jonkers, F. Lamers, S.M. Evers, and et al. Cost-utility estimates in depression: does the valuation method matter? J Ment Health Policy Econ 13 2010 189 197
73. R. Arbuckle, M.A. Frye, M. Brecher, and et al. The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder Psychiatry Res 165 2009 163 174
74. I.W. Miller, G.I. Keitner, A.F. Schatzberg, and et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine J Clin Psychiatry 59 1998 608 619
75. G.E. Simon, M. VonKorff, J.H. Heiligenstein, and et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants JAMA 275 1996 1897 1902
76. G.E. Simon, J. Heiligenstein, D. Revicki, and et al. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial Arch Fam Med 8 1999 319 325
77. D.A. Revicki, G.E. Simon, K. Chan, and et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment J Fam Pract 47 1998 446 452
78. K. Kroenke, S.L. West, R. Swindle, and et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial JAMA 286 2001 2947 2955
79. O.C. Gleason, W.R. Yates, M.D. Isbell, and M.A. Philipsen An open-label trial of citalopram for major depression in patients with hepatitis C J Clin Psychiatry 63 2002 194 198
80. J.H. Kocsis, A. Schatzberg, A.J. Rush, and et al. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo Arch Gen Psychiatry 59 2002 723 728
81. C.M. Miner, E.B. Brown, J.S. Gonzales, and R. Munir Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression J Clin Psychiatry 63 2002 232 240
82. D.G. Contopoulos-Ioannidis, A. Karvouni, I. Kouri, and J.P. Ioannidis Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review BMJ 338 2009 a3006
83. K.H. Sheehan, and D.V. Sheehan Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale Int Clin Psychopharmacol 23 2008 70 83
84. D.R. Ledley, R.G. Heimberg, D.A. Hope, and et al. Efficacy of a manualized and workbook-driven individual treatment for social anxiety disorder Behav Ther 40 2009 414 424
85. M.J. Detke, C.G. Wiltse, C.H. Mallinckrodt, and et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial Eur Neuropsychopharmacol 14 2004 457 470
86. A.J. Rush, and A. Bose Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting Depress Anxiety 21 2005 26 32
87. R.M. Berman, M. Fava, M.E. Thase, and et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants CNS Spectr 14 2009 197 206
88. E. Smeraldi Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study J Affect Disord 48 1998 47 56
89. A.C. Leon, M. Olfson, L. Portera, and et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale Int J Psychiatry Med 27 1997 93 105
90. M. Olfson, W.E. Broadhead, M.M. Weissman, and et al. Subthreshold psychiatric symptoms in a primary care group practice Arch Gen Psychiatry 53 1996 880 886
91. D. Stevanovic Quality of Life Enjoyment and Satisfaction Questionnaire-short form for quality of life assessments in clinical practice: a psychometric study J Psychiatr Ment Health Nurs 18 2011 744 750
92. S.L. Bishop, D.P. Walling, S.G. Dott, and et al. Refining quality of life: validating a multidimensional factor measure in the severe mentally ill Qual Life Res 8 1999 151 160
93. K. Wyrwich, N. Harnam, D.A. Revicki, and et al. Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire Int Clin Psychopharmacol 24 2009 289 295
94. A. Schrag, C. Selai, M. Jahanshahi, and N.P. Quinn The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease J Neurol Neurosurg Psychiatry 69 2000 67 73
95. J. Raskin, C.G. Wiltse, A. Siegal, and et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial Am J Psychiatry 164 2007 900 909
96. G. Serafini, M. Pompili, C.A. Del, and et al. Duloxetine versus venlafaxine in the treatment of unipolar and bipolar depression Clin Ter 161 2010 321 327
97. R.W. Lam, J. Endicott, M.A. Hsu, and et al. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine Int Clin Psychopharmacol 29 2014 239 251